CIP2A and Miyoshi myopathy: Increasing evidence demonstrates that higher CIP2A expression promotes cancer progression, suggesting that CIP2A could be an attractive therapeutic target for the treatment of human cancers.1,31 Next, we investigated the CIP2A expression status and its correlation with clinicopathological features of patients with MM.